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Gregory L. Moneta, MD, Section EditorInhibitory Effects of Calcitonin Gene-Related Peptides on Experimen-
tal Vein Graft Disease
Zhang X, Zhuang J, Wu H, et al. Ann Thorac Surg 2010;90:117-23.
Conclusion: Transfection of calcitonin gene-related peptide inhibits
inflammatory mediator expression, macrophage infiltration, and neointimal
hyperplasia in experimental vein graft disease.
Summary: The mechanisms of intimal hyperplasia are complex, and
include interactions with inflammatory cells, inflammatory mediators, and
smooth muscle cells. In particular, macrophages appear necessary for the
initiation of intimal hyperplasia. Calcitonin gene-related peptide (CGRP) is
a biologically active amino peptide, 37 amino acids in length. Studies have
shown that CGRP can inhibit inflammatory cells and expression of inflam-
matory mediators such as tumor necrosis factor (TNF)- and NCP-1 that
appear important in intimal hyperplasia (Li W, et al, Am J Cell Physiol
2006;291:C456-65). CGRP can also inhibit hyperplasia of vascular smooth
muscle and protect endothelial cell function (Deng W, et al, Life Sci
2006;78:1830-8 and Ye F, et al, Vasc Pharm 2007;46:238-46). The authors
sought to evaluate the effects of CGRP expressed by an adeno-associated
virus vector (AAV2) gene transfer on macrophage infiltration and inflam-
matory mediators of vein graft disease in a rabbit model. The hypothesis was
that the transfected CGRP gene could inhibit macrophage infiltration and
expression of inflammatory mediators and thus suppress intimal hyperplasia.
Rabbit jugular vein grafts were incubated ex vivo in a solution of
adeno-associated virus vectors containing the CGRP gene (AAV2/
1.CGRP) or Escherichia coli B-galactosidase (LacZ), or a saline solution.
These grafts were then interposed in the carotid artery. CGRP gene expres-
sion was identified by a reverse transcription polymerase chain reaction
(PCR) and LacZ gene expression was identified by X-gal staining. At 4
weeks, intima/media ratios were determined, and macrophages were iden-
tified with CD68 antibody immunochemistry. Inflammatorymediators were
measured with real-time PCR. CGRP and LacZ gene expression were
positive at 4 weeks postoperatively. The intima/media ratio was significantly
inhibited in the AAV2/1.CGRP group. Also significantly inhibited in the
AAV2/1.CGRP group were monocyte chemoattractant protein-1, TNF-,
inducible nitric oxide synthase, and matrix metalloproteinase-9. Macro-
phage infiltration was also inhibited.
Comment: The authors’ experiment supported their hypothesis. The
report is brief and does not delineate specific patterns of gene expression and
thus does not allow precise determination of mechanism. However, the end
result—very effective inhibition of intimal hyperplasia—is interesting. Vas-
cular and cardiovascular surgeons remember the recent disappointments of
the PREVENT 3 and PREVENT 4 trials, where novel therapy directed at
the genetic level failed to suppress intimal hyperplasia. With respect to
inhibiting intimal hyperplasia, the chiasm between promising basic bench
research and clinical relevance in humans remains wide. This is interesting
work, but given the history of this field, any optimism should be tempered
with caution.
Leiomyosarcoma of the Inferior Vena Cava: Clinicopathologic Study of
40 Cases
Laskin WB, Fanburg-Smith JC, Burke AP, et al. Am J Surg Pathol 2010;34:
1873-81.
Conclusion: Macroscopic resection of a localized vena cava leiomyo-
sarcoma is the best chance for long-term survival. Suprahepatic tumors are
associated with early death, and compromised liver function correlates with
overall poor survival.
Summary: Leiomyosarcoma is the most common sarcoma that affects
the venous system, and nearly 50% arise in the inferior vena cava (Kavorkian
J, Cento DP, Surgery 1973;73:390-400). However, leiomyosarcoma of the
inferior vena cava accounts for only about 0.5% of adult soft tissue sarcomas
(Hollebeck ST, et al, J Am Coll Surg 2003;197:575-9). Overall prognosis is
thought to be poor, with metastatic disease occurring primarily to liver and
lung, and recurrent disease contributing to tumor-related mortality as well.
In this report, the authors detailed the clinical pathologic features and
follow-up data on 40 patients with inferior vena cava leiomyosarcoma. The
study cohort consisted of 31 women and 9 men (mean age, 53 years) whose
material was accessioned to the Armed Forces Institute of Pathology be-
tween 1976 and 2008. Median tumor size was 8.5 cm (range, 2.5-15.0 cm).
The middle segment of the inferior vena cava was most often involved. Most
tumors grew extraluminally. Eleven of the 33 patients managed by complete
radical resection had involved surgical margins. Twenty of 34 patients with
clinical follow-up died of sarcoma-related complications, and 26% died of
unknown causes. Survival rates after resection without documented residual
1420macroscopic disease were 50% at 5 years and 22% at 10 years. Factors that
statistically correlated with death at 2 years were suprahepatic vena cava
involvement, right atrial involvement, predominantly intraluminal tumor
growth, and residual postsurgical macroscopic disease. Univariate analysis
suggested intraluminal tumor (P .03), liver entry or failure (P .01), and
moderate to poor tumor differentiation (P  .03) were associated with
increased tumor-related mortality. On multivariate analysis, only compro-
mised liver function (P  .01) correlated with mortality.
Comment: This is a very large series of leiomyosarcoma of the inferior
vena cava and confirms a poor prognosis associated with these tumors and
the seemingly obvious fact that incomplete resection is associated with a
poor short-term survival. Nevertheless, it is interesting to note that the
growth pattern extraluminal vs intraluminal and the status of the patient’s
overall hepatic function also appear to be important prognostic factors in
patients with this rare malignancy.
Randomized Clinical Trial of VNUS®ClosureFAST™Radiofrequency
Ablation versus Laser for Varicose Veins
Shepherd AC, Gohel MS, Brown LC, et al. Br J Surg 2010;97:810-8.
Conclusion: Radiofrequency ablation (RFA) using VNUS Closure-
FAST (VNUS Medical Technologies, San Jose, Calif) is associated with less
postprocedural pain than endovenous laser ablation (EVLA). Clinical and
quality of life improvements for the two procedures are similar at 6 weeks.
Summary: Endovenous ablative procedures have largely replaced stan-
dard saphenous stripping for treatment of saphenous reflux in patients with
primary varicose veins. At the time of publication of this article, only one
small randomized trial has compared VNUS ClosureFAST and EVLA
(Almeida JI et al, J Vasc Interv Radiol 2009;20:752-9). This current study
compares the most utilized technique for EVLA in Great Britain (980-nm
wavelength and bare fiber) vs the most popular RFA system in Great Britain
(VNUS ClosureFAST). Consecutive patients with primary great saphenous
vein reflux were randomized to EVLA or RFA at a single center. The primary
outcome measure was postprocedural pain at 3 days. Secondary outcome
measures were quality of life at 6 weeks, as determined by the Aberdeen
Varicose Vein Questionnaire (AVVQ) and Short Form 12 (SF-12), and
clinical improvement using the Venous Clinical Severity Score (VCSS).
Analysis was on an intention-to-treat basis. There were 64 patients random-
ized to EVLA and 67 to RFA. At 3 days, mean (SD) pain scores were 26.4
(22.1) mm for RFA and 36.8 (22.5) mm for EVLA (P  .010). Over 10
days, mean (SD) pain scores were 22.0 (19.8) mm for RFA vs 34.3 (21.1)
mm for EVLA respectively (P  .001). Mean number of analgesic tablets
used over 3 days and over 10 days was lower for RFA (P .003) than EVLA
(P .001). There were no differences in AVVQ, SF-12, and VCSS scores at
6 weeks between the two groups (P  .887, P  .076, P  .449, respec-
tively).
Comment: The study demonstrated that VNUS ClosureFAST results
in significantly less pain than 980-nm EVLA for ablation of the great
saphenous veins in treatment of patients with varicose veins. The study
supports previous publications that demonstrate less postprocedural pain
after RFA but failed to show differences in outcomes after 1 month (Mor-
risson N, Semin Vasc Surg 2005;18:15-8 and Almeida J, et al, J Vasc Interv
Radiol 2009;20:752-9). However, EVLA is continuing to be refined. There
are newer fibers with longer wave lengths and jacketed laser fibers that
appear to be associated with lower postintervention pain scores (Almeida J,
et al. Vasc Endovasc Surg 2009;43:467-72). Data comparing these new
devices with VNUS closure system will also eventually be required.
Recurrent Deep Vein Thrombosis: Long-Term Incidence and Natural
History
Labropoulos N, Jen J, Jen H, et al. Ann Surg 2010;251:749-53.
Conclusion: Deep vein thrombosis (DVT) recurrence is associated
with age65 and an elevated residual thrombus burden. Pulmonary embo-
lism (PE) occurs frequently and is a common cause of death.
Summary: The reported incidence of recurrent venous thromboem-
bolism (VTE) is up to 40% at 10 years (Prandoni P, Hematologica 2007;
92:199-205), with most recurrent VTE occurring after anticoagulation has
been discontinued. Whereas much is known about recurrent DVT, there are
actually few long-term studies examining factors influencing recurrent DVT
and its natural history. The authors enrolled both inpatients and outpatients
with acute DVT in their study. They excluded patients with previous VTE,
active cancer, those already on anticoagulation, or those requiring perma-
nent anticoagulation. Also excluded were patients with short life expectancy
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monitored with clinical examination at 3, 6, and 12 months and annually for
at least 5 years. Patients with proximal DVT were anticoagulated for at least
6 months. Those with calf DVT were anticoagulated for 3 months or were
monitored with ultrasound imaging for 3 weeks. If the calf DVT progressed,
the patients were anticoagulated; if it did not, they remained on compression
stockings and aspirin or nonsteroidal anti-inflammatory drugs. Patients
underwent duplex ultrasound imaging at least twice in the first year and at
any time when there were symptoms suggestive of recurrent VTE. Duplex
examinations were also performed at 5 years and anytime later for those with
longer follow-up. DVT recurrence was defined as thrombus in a new
location from the original DVT when the extent of thrombus at the follow
up examination was 9 cm, when a previously recanalized segment subse-
quently exhibited non-compressibility, and when thrombus thickness was
2 mm for distal veins and 4 mm for proximal veins. This prospective
observational study enrolled 153 consecutive patients. Location and extent
of the initial DVT, PE, recurrent VTE, causes of mortality, signs and
symptoms of post-thrombotic syndrome, and risk factors of VTE were
recorded.
Recurrent VTE occurred in 26.1% by 5 years. Patients who had both
proximal and distal DVT had similar recurrence rates compared with those
patients with proximal DVT alone (17 of 48 [35%] vs 12 of 49 [24%], P 
.27). There appeared to be a trend toward higher recurrence rates in patients
with proximal and distal DVT than those with calf DVT alone (P  .08). A
higher recurrence was associated with unprovoked DVT (relative risk [RR],
2.9; 95% confidence interval [CI], 1.5-5.7; P .01) and age65 years (RR,
1.5; 95% CI, 1-23; P .025;). There was no demonstrated increased risk of
recurrence with thrombophilia (P  .21). There was low recurrence in
patients with DVT associated with surgery or trauma (P  .001). Increased
severity of post thrombotic syndrome was associated with ipsilateral recur-
rence (RR, 1.6; 95%CI, 1.4-2.2; P .001). PE was diagnosed 47 times, and
12 of 47 (25%) incidences of PE were fatal.
Comment: The study has severe limitations due to sample size. The
number of patients is too small to provide meaningful subgroup analysis.
The number of patients ultimately dying of PE is a bit shocking, but perhaps
what is most interesting in this field is the increasing frequency of reports
contradicting the widely held belief that thrombophilia is a risk factor for
recurrence of VTE. Clearly, as in this study, many patients with thrombo-
philia have other risk factors for VTE that make it difficult to independently
assess the impact of thrombophilia on VTE recurrence. Despite the results
here, until larger and better studies have examined the impact of thrombo-
philia on VTE recurrence, it may be best to still consider thrombophilia as a
risk factor for recurrent VTE.
Relation Between Preoperative and Intraoperative New Wall Motion
Abnormalities in Vascular Surgery Patients: A Transesophageal Echo-
cardiographic Study
Galal W, Hoeks SE, Flu WJ, et al. Anesthesiology 2010;112:557-66.
Conclusion: There is a poor correlation between new wall motion
abnormalities (NWMAs) observed intraoperatively using transesophageal
echocardiography (TEE) and preoperative stress-induced NWMAs assessed
by dobutamine echocardiography.
Summary: Intraoperative TEE can detect regional wall motion abnor-
malities in patients undergoing major noncardiac surgery. However, it is
unclear whether NWMAs detected intraoperatively with TEE actually cor-
relate with abnormalities detected preoperatively with noninvasive stress
testing. The authors sought to determine whether wall motion abnormali-
ties identified with dobutamine echocardiography correlate with those ob-
served intraoperatively with TEE.
Fifty-four patients undergoing major vascular surgery underwent pre-
operative dobutamine echocardiography and intraoperative TEE. A seven-
wall model scoring system was used to determine the locations of left
ventricular rest wall motion abnormalities and NWMAs discovered with
preoperative stress testing or with intraoperative TEE. Postoperative cardiac
troponin levels, myocardial infarction, and cardiac death were noted during
a 30-day follow-up. Wall motion abnormalities at rest were detected by
dobutamine echocardiography in 17 patients (31%). TEE noted NWMAs in
16 patients (30%). NWMAs were induced with dobutamine in 17 patients
(31%). NWMAs were observed by TEE in 23 patients (43%,   0.65).
There was excellent agreement between preoperative and intraoperative rest
wall motion abnormalities (  0.92); however, agreement for preoperative
and intraoperative new wall motion abnormalities in different locations was
poor (  0.26-0.44). A composite cardiac end point of increased troponin
levels, myocardial infarction, or cardiac death occurred in 15 patients (26%),
of whom 10 patients (67%) experienced both preoperative and intraopera-
tive NWMAs. Only intraoperative NWMAs were observed in four (27%). In
the six patients who experienced a postoperative myocardial infarction, the
location of the electrocardiographic changes correlated with intraoperatively
observed NWMAs by TEE.
Comment: In this series there were no cardiac deaths or postoperative
myocardial infarctions in patients without intraoperative NWMAs. Because
reproducibility of wall motion abnormalities at different perioperative timeswas not achievable in this study, the suggestion is that optimized medical
therapy remains superior over invasive interventions focused on preoperative
detection of culprit lesions. The data indicate patients with intraoperative
NWMAs detected by TEE are perhaps the highest risk group for periopera-
tively significant cardiac events. Such patients demand perhaps the most
assiduous perioperative management of cardiac parameters.
Risk Factors and Outcome of New-Onset Cardiac Arrhythmias in
Vascular Surgery Patients
Winkle TA, Schouten O, Hoeks SE, et al. Am Heart J 2010;159:1108-15.
Conclusion: Perioperative arrhythmias are common after vascular
surgeries. Elderly patients and those with reduced left ventricular function
are particularly prone to postoperative arrhythmias.
Summary:Cardiac arrhythmia occurring postoperatively can be seen in
up to 20% of patients undergoing noncardiac surgery (Brathwaite D, et al,
Chest 1998;114:462-8 and Walsh SR et al, Ann R Coll Surg Engl 2007;89:
91-5). The risk of cardiovascular events is especially elevated in noncardiac
vascular surgical patients (Schouten O et al, Eur Heart J 2008;29:283-4).
Many events are asymptomatic and often transient and unpredictable, sug-
gesting the true prevalence may be underestimated. The current study
focused on vascular surgical patients and was designed to determine the true
prevalence of cardiac arrhythmias in this population, identify operative risk
factors leading to new-onset cardiac arrhythmias, and assess the impact of
these new arrhythmias on postoperative outcome.
The study included 515 vascular surgical patients without a history of
arrhythmia. Assessed were left ventricular function (LVF), determined by
N-terminal pro-B-type natriuretic peptide levels and echocardiography,
inflammatory status, and cardiac risk factors. New onset arrhythmias and
ischemia were identified with 72-hour continuous electrocardiographic
recordings. Patients were evaluated for atrial fibrillation, sustained ventric-
ular tachycardia, supraventricular tachycardia, and ventricular fibrillation.
There was a new onset of arrhythmia in 55 patients (11%), including atrial
fibrillation in 4%, ventricular tachycardia in 7%, supraventricular tachycardia
in 1%, and ventricular fibrillation in 0.2%. Arrhythmia was preceded by
ischemia in 10 of 55 patients. Reduced LVF and increased age were risk
factors for development of arrhythmia. Multivariant analysis indicated that
perioperative arrhythmias were associated with long-term cardiovascular
events independent of perioperative ischemia (hazard ratio, 2.2; 95% confi-
dence interval, 1.3-3.8; P  .004).
Comment:More than 30 years ago, Goldman published a prospective
series of patients undergoing major noncardiac surgery, and only 4% devel-
oped postoperative supraventricular arrhythmias (Goldman L, Chest 1978;
73:450-4). One conclusion was that postoperative supraventricular arrhyth-
mias were often transient, and the most important thing was to correct the
cause of the arrhythmia. The number of each type of arrhythmia occurring in
this study did not permit meaningful subset analysis. The association of
arrhythmias with older age and preoperatively decreased LVF is not all that
surprising. Currently, many vascular surgical patients are routinely subjected
to telemetry monitoring. Given the number of arrhythmias identified in this
study, the current data may question the use of such a blanket policy for
patients without known preoperative left ventricular dysfunction.
The Phosphodiesterase Inhibitor Cilostazol Induces Regression of
Carotid Atherosclerosis in Subjects With Type 2 Diabetes Mellitus
Principal Results of the Diabetic Atherosclerosis Prevention by Cilosta-
zol (DAPC) Study: A Randomized Trial
Katakami N, Kim Y-S, Kawamori R, et al. Circulation 2010;121:2584-91.
Conclusion: Cilostazol provides greater inhibition of progression of
carotid intima-medial thickness than aspirin in patients with type 2 diabetes
mellitus.
Summary: It appears patients with diabetes without previous myocar-
dial infarction have as high a risk of myocardial infarction as patients without
diabetes and previous myocardial infarction (Haffner SM, et al, N Engl
J Med 1998;339:229-34). On the basis of this, some have advocated that
primary prevention in patients with diabetes may be indicated. Guidelines
suggest that individuals with risk factors for coronary heart disease, such as
diabetes mellitus, should take aspirin for primary and secondary prevention,
although the ability of aspirin to effectively serve as a primary preventive
agent is controversial (American Diabetes Association, Diabetes Care 2007;
30:s4-41). There has been some suggestion that cilostazol may be effective
in preventing cardiovascular events in patients with type 2 diabetes mellitus
(Shinohara Y, et al, Cerebrovasc Dis 2008;26:63-70). This study therefore
compared the ability of two antiplatelet agents, aspirin and cilostazol, to
prevent progression of carotid intima-media thickness. This was a prospec-
tive, randomized, open, blinded end point study conducted in four East
Asian countries. The study enrolled 329 type 2 diabetic patients suspected of
peripheral arterial disease (PAD). Patients were eligible if they were aged 40
to 85 years at the time of enrollment and were suspected of PAD on the basis
of an ankle-brachial index 1.0, poor pulses, or clinical symptoms of PAD.
Patients were allocated to receive aspirin (81-100 mg/d) or cilostazol
